DLP: data lock point

The data lock point (DLP) is the cut-off date for the data included in a periodic safety report, counted from the product's reference or birth date.

Also known as: PSUR data lock point, data lock date

4 min readUpdated

Reviewed by Gosia Luksza, CEO at Regunaut

At a glance

Defined in
ICH E2C(R2) and GVP Module VII
Set by
The EURD list for listed substances; otherwise the frequency in the authorisation
Starts the clock
Day zero for the 70 or 90-day PSUR submission deadline
Anchor dates
International birth date; EU reference date under Article 107c(5) of Directive 2001/83/EC

How it works

The data lock point is the date designated as the cut-off for data to be included in a periodic safety update report. Everything the holder has received up to and including that date goes into the report. Anything later waits for the next one, unless it is important enough to mention as late-breaking information. The term comes from ICH E2C(R2) and is used throughout GVP Module VII. The same idea applies to other periodic documents: a development safety update report has its own data lock point, counted from the development international birth date, and a risk management plan states the data lock point of the safety data it is based on.

Data lock points are counted from an anchor date. The international birth date (IBD) is the date of the first marketing authorisation for any product containing the active substance, granted to any company in any country in the world. The EU reference date, or Union reference date, is defined in Article 107c(5) of Directive 2001/83/EC as the date of the first marketing authorisation in the Union of a medicine containing the active substance or combination or, where that cannot be ascertained, the earliest known date of authorisation for such a medicine. For substances on the EURD list, the list publishes the Union reference date, the PSUR frequency and the next data lock point, so that every holder of a product containing the substance reports on the same interval and the reports can be assessed together. For products outside the list, data lock points follow from the frequency that applies to the authorisation.

The data lock point is day zero of the submission clock. The report is due within 70 calendar days where it covers up to 12 months and within 90 calendar days where it covers more. That makes the weeks after the lock the busiest in the cycle: case data are frozen, exposure and sales figures collected from every market, signals closed out, and the evaluation written and reviewed. Holders who market the same substance in other regions often want one birth date worldwide, so that one report with one data lock point can go to several authorities. Article 107c(6) lets a holder ask for the Union reference date or the frequency to be changed, among other grounds to achieve international harmonisation.

What goes wrong

A calendar that still counts from the product's own authorisation date after the substance has been added to the EURD list; a data lock point that moved in a list update and was not picked up; safety data and exposure data cut on different dates, so the numbers in the report do not reconcile; partners and licensees working to their own lock dates; cases received before the lock but entered after it, which then fall between two reports; and the 70 or 90 days counted from the end of the month instead of from the lock date. After a transfer of the marketing authorisation, the new holder inherits the data lock points and should confirm them against the list before the first report is due.

Timing

  1. Reference date

    The international birth date or EU reference date fixes the cycle that data lock points are counted from.

  2. Data lock point

    Day 0. Data for the report are frozen.

  3. Day 70

    PSUR due where the interval covered is 12 months or less.

  4. Day 90

    PSUR due where the interval covered is longer than 12 months.

The data lock point is day zero. A PSUR covering up to 12 months is due within 70 calendar days of it, and one covering a longer interval within 90 calendar days. A new or changed entry in the EURD list, including a moved data lock point, applies six months after publication.

What teams do with it in Regunaut

One job in the platform that turn on DLP, each part of a wider workflow.

What the 2026 EU pharma package changes

Under the new pharma package (not yet in force), the default PSUR cycle for authorisations without a set frequency changes and updates to the EURD list take effect after four months instead of six, which shortens the notice a holder gets of a moved data lock point; see PSUR changes.

DLP: common questions

What is a data lock point in pharmacovigilance?

It is the cut-off date for the data included in a periodic safety report such as a PSUR. Cases and other information received up to that date are evaluated in the report; later information goes into the next one. The date also starts the submission clock: 70 calendar days for a PSUR covering up to 12 months, 90 for a longer interval.

What is the difference between the international birth date and the EU reference date?

The international birth date is the date of the first marketing authorisation of a product containing the active substance anywhere in the world, to any company. The EU reference date is the date of the first authorisation in the Union of a medicine containing the substance, as defined in Article 107c(5) of Directive 2001/83/EC. The EURD list uses the EU reference date to align the PSURs of all holders of the same substance.

How is the PSUR data lock point determined?

For a substance on the EURD list, the list states the next data lock point and the submission deadline, and they override the dates in the marketing authorisation. For other products the data lock point follows from the PSUR frequency set as a condition of the authorisation or, failing that, from the standard schedule in Article 107c of Directive 2001/83/EC.

Sources

  1. European Medicines Agency: Periodic safety update reports (PSURs)
  2. EUR-Lex: Directive 2001/83/EC on the Community code relating to medicinal products for human use (Article 107c)

Put your DLP question to Workbench

Workbench answers regulatory questions from EUR-Lex, EMA, national agencies and your own documents, with every claim linked to its source. Start free with welcome credits.